China Pioneer Pharma Holdings Limited
Символ: 1345.HK
HKSE
1.42
HKDПазарна цена днес
13.7568
Съотношение P/E
-0.2145
Коефициент PEG
1.67B
MRK Cap
- 0.04%
Доходност на DIV
China Pioneer Pharma Holdings Limited (1345-HK) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 953.32 | 124.4 | 289 | 402.1 | ||||||||||||
balance-sheet.row.short-term-investments | 341 | 10 | 75 | 177.2 | ||||||||||||
balance-sheet.row.net-receivables | 1555.99 | 448.4 | 413.2 | 251.8 | ||||||||||||
balance-sheet.row.inventory | 1263.78 | 417.9 | 321.1 | 294.9 | ||||||||||||
balance-sheet.row.other-current-assets | 741.88 | 126.2 | 186.6 | 241.5 | ||||||||||||
balance-sheet.row.total-current-assets | 4173.98 | 1106.9 | 1134.9 | 1013.1 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 868.72 | 247.4 | 221.6 | 91.1 | ||||||||||||
balance-sheet.row.goodwill | 25.09 | 6.2 | 6.2 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 143.24 | 30.2 | 37 | 45.9 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 168.33 | 36.4 | 43.3 | 45.9 | ||||||||||||
balance-sheet.row.long-term-investments | 478.33 | 117.1 | 156.2 | 82.2 | ||||||||||||
balance-sheet.row.tax-assets | 18.75 | 2.3 | 8.6 | 12 | ||||||||||||
balance-sheet.row.other-non-current-assets | 4.25 | 20.7 | -8.6 | -12 | ||||||||||||
balance-sheet.row.total-non-current-assets | 1538.38 | 424 | 421 | 219.2 | ||||||||||||
balance-sheet.row.other-assets | 134.51 | 0 | 15.8 | 96.1 | ||||||||||||
balance-sheet.row.total-assets | 5846.87 | 1530.9 | 1571.7 | 1328.5 | ||||||||||||
balance-sheet.row.account-payables | 979.45 | 284.9 | 329.3 | 262 | ||||||||||||
balance-sheet.row.short-term-debt | 252.52 | 61.3 | 29.6 | 14 | ||||||||||||
balance-sheet.row.tax-payables | 88.67 | 17.8 | 39.8 | 24.9 | ||||||||||||
balance-sheet.row.long-term-debt-total | 28.99 | 12.7 | 8 | 0.1 | ||||||||||||
Deferred Revenue Non Current | 171.13 | 41.4 | 43.6 | 43.6 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 87.51 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 438.83 | 0 | 143.5 | 86.2 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 287.63 | 70.4 | 76.3 | 69.3 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 31.85 | 14 | 8.7 | 0.2 | ||||||||||||
balance-sheet.row.total-liab | 1863.65 | 513.1 | 549.2 | 417.5 | ||||||||||||
balance-sheet.row.preferred-stock | 279.76 | 0 | 84.1 | 59 | ||||||||||||
balance-sheet.row.common-stock | 309.6 | 77.4 | 77.4 | 77.6 | ||||||||||||
balance-sheet.row.retained-earnings | 2351.25 | 634.9 | 594.8 | 444.2 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 649.28 | 929 | -84.1 | -59 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 337.72 | -634.9 | 335.6 | 386.2 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 3927.61 | 1006.4 | 1007.8 | 908 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 5846.87 | 1530.9 | 1571.7 | 1328.5 | ||||||||||||
balance-sheet.row.minority-interest | 55.61 | 11.3 | 14.7 | 3 | ||||||||||||
balance-sheet.row.total-equity | 3983.21 | 1017.8 | 1022.5 | 911 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 5846.87 | - | - | - | ||||||||||||
Total Investments | 809.33 | 117.1 | 231.2 | 259.4 | ||||||||||||
balance-sheet.row.total-debt | 281.52 | 74 | 37.6 | 14.1 | ||||||||||||
balance-sheet.row.net-debt | -330.8 | -40.4 | -176.4 | -210.8 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 381.01 | 235.3 | 142.6 | 52.4 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 32.58 | 13.6 | 12.9 | 8.4 | |||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.change-in-working-capital | -287.14 | -193.5 | 226.3 | -147.3 | |||||||||||||
cash-flows.row.account-receivables | -166.57 | -168 | 66.2 | -65.3 | |||||||||||||
cash-flows.row.inventory | -118.54 | -25.5 | 160.2 | -82.1 | |||||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-working-capital | -2.03 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-non-cash-items | -151.85 | 37.9 | -139.8 | 160.8 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -25.39 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -105.19 | -74.3 | -16.6 | -34.9 | |||||||||||||
cash-flows.row.acquisitions-net | -6.21 | -26.7 | -2.4 | -20.9 | |||||||||||||
cash-flows.row.purchases-of-investments | 0 | -717.2 | -2020.3 | -512.9 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 798.1 | 1976.4 | 570.5 | |||||||||||||
cash-flows.row.other-investing-activites | 167.92 | 7 | 71.4 | 22.1 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 56.51 | -13 | 8.4 | 23.9 | |||||||||||||
cash-flows.row.debt-repayment | -0.07 | -1.1 | 0 | -0.1 | |||||||||||||
cash-flows.row.common-stock-issued | 32.37 | 26.9 | 10.4 | -2.8 | |||||||||||||
cash-flows.row.common-stock-repurchased | -48.51 | -25.8 | -10.3 | -2.8 | |||||||||||||
cash-flows.row.dividends-paid | -162.16 | -84.7 | -129.9 | -111.9 | |||||||||||||
cash-flows.row.other-financing-activites | 69.15 | -6.4 | -10.4 | -135.5 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -141.59 | -91 | -140.3 | -253 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.04 | -0.1 | -0.3 | -0.4 | |||||||||||||
cash-flows.row.net-change-in-cash | -110.42 | -10.8 | 109.8 | -155.3 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 612.32 | 214 | 224.9 | 115 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 722.74 | 224.9 | 115 | 270.3 | |||||||||||||
cash-flows.row.operating-cash-flow | -25.39 | 93.3 | 242.1 | 74.2 | |||||||||||||
cash-flows.row.capital-expenditure | -105.19 | -74.3 | -16.6 | -34.9 | |||||||||||||
cash-flows.row.free-cash-flow | -130.58 | 19 | 225.4 | 39.4 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3122.71 | 1566.7 | 1556 | 1434.8 | ||||||||||||||
income-statement-row.row.cost-of-revenue | 1674.01 | 898.4 | 775.6 | 662.8 | ||||||||||||||
income-statement-row.row.gross-profit | 1448.7 | 668.2 | 780.5 | 772 | ||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||
income-statement-row.row.selling-general-administrative | 194.19 | - | - | - | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 890.35 | - | - | - | ||||||||||||||
income-statement-row.row.other-expenses | 0 | 1.6 | 4.8 | 2.7 | ||||||||||||||
income-statement-row.row.operating-expenses | 985.88 | 488 | 496.6 | 574.6 | ||||||||||||||
income-statement-row.row.cost-and-expenses | 2659.89 | 1386.5 | 1272.1 | 1237.4 | ||||||||||||||
income-statement-row.row.interest-income | 12.13 | 0.6 | 10.6 | 4 | ||||||||||||||
income-statement-row.row.interest-expense | 0 | 2.5 | 1.7 | 0.9 | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 890.35 | - | - | - | ||||||||||||||
income-statement-row.row.total-other-income-expensenet | 109.21 | 46.9 | 62.3 | 14.2 | ||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 1.6 | 4.8 | 2.7 | ||||||||||||||
income-statement-row.row.total-operating-expenses | 109.21 | 46.9 | 62.3 | 14.2 | ||||||||||||||
income-statement-row.row.interest-expense | 0 | 2.5 | 1.7 | 0.9 | ||||||||||||||
income-statement-row.row.depreciation-and-amortization | 30.63 | 18.9 | 13.2 | 12.7 | ||||||||||||||
income-statement-row.row.ebitda-caps | 396.36 | - | - | - | ||||||||||||||
income-statement-row.row.operating-income | 365.73 | 133.5 | 232.2 | 187.2 | ||||||||||||||
income-statement-row.row.income-before-tax | 474.94 | 180.4 | 294.5 | 201.4 | ||||||||||||||
income-statement-row.row.income-tax-expense | 116 | 51.5 | 64.5 | 60.6 | ||||||||||||||
income-statement-row.row.net-income | 381.01 | 145.7 | 235.3 | 142.6 |
Често задавани въпроси
Какво е China Pioneer Pharma Holdings Limited (1345.HK) общи активи?
China Pioneer Pharma Holdings Limited (1345.HK) общите активи са 1530905000.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 1566673000.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е -0.127.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е -0.127.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е 0.093.
Какъв е общият приход на предприятието?
Общият приход е 0.085.
Каква е China Pioneer Pharma Holdings Limited (1345.HK) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е 145718000.000.
Какъв е общият дълг на фирмата?
Общият дълг е 74020000.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 488030000.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 114427000.000.